All In Biotech

Drug Trial Radar · NCT04273945

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients With Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period With Macitentan 75 mg

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 935 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

935

Actual

Start

Jun 30, 2020

Primary completion

Oct 7, 2025

Study completion Feb 20, 2029

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Feb 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • Macitentan 10 mgDrug

    Participants will receive macitentan 10 mg film-coated tablets orally.

  • Macitentan 37.5 mgDrug

    Participants will receive macitentan 37.5 mg film-coated tablets orally.

  • Macitentan 75 mgDrug

    Participants will receive macitentan 75 mg film-coated tablets orally.

  • PlaceboDrug

    Participants will receive matching placebo film-coated tablets orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double-blind Treatment Period: Time to First Clinical Events Committee (CEC)-adjudicated Morbidity or Mortality (M/M) EventsTime frame: Up to 4 years

Locations

274 sites in 42 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona

  • Arizona Pulmonary Specialists, Ltd

    Scottsdale, Arizona

  • Scripps Memorial Hospital

    La Jolla, California

  • USC Keck

    Los Angeles, California

  • Jeffrey S. Sager, MD Medical Corporation

    Santa Barbara, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • National Jewish Health

    Denver, Colorado

  • Cleveland Clinic

    Weston, Florida

  • Piedmont Healthcare

    Atlanta, Georgia

  • Northside Hospital

    Atlanta, Georgia

  • Advocate Christ Medical Center

    Oak Lawn, Illinois

  • Indiana University

    Indianapolis, Indiana

  • St. Vincent Medical Group, Inc.

    Indianapolis, Indiana

  • University Of Iowa - Hospitals & Clinics

    Iowa City, Iowa

  • Norton Pulmonary Specialists

    Louisville, Kentucky

  • Louisiana State University

    New Orleans, Louisiana

  • University of Michigan

    Ann Arbor, Michigan

  • Troy Beaumont

    Troy, Michigan

  • Washington University School Of Medicine

    St Louis, Missouri

  • Saint Louis University Academic Pavillion

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Reno Heart Institute

    Reno, Nevada

  • Winthrop University Hospital

    Mineola, New York

  • Mount Sinai

    New York, New York

  • Columbia University

    New York, New York

  • Stony Brook University Medical Center

    Stony Brook, New York

  • Duke

    Durham, North Carolina

  • Lindner Clinical Trial Center/Christ Hospital

    Cincinnati, Ohio

  • Integris Baptist Office

    Oklahoma City, Oklahoma

  • The Oregon Clinic Pulmonary West

    Beaverton, Oregon

  • The Oregon Clinic

    Portland, Oregon

  • Oregon Health And Science University

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Allegheny General Hospital of Research

    Pittsburgh, Pennsylvania

  • Lankenau Medical Center

    Wynnewood, Pennsylvania

  • AnMed Health

    Anderson, South Carolina

  • UT Southwestern Medical Center

    Dallas, Texas

  • Baylor College of Medicine (BCM) - Baylor Heart Clinic

    Houston, Texas

  • Baylor Scott White - Plano

    Plano, Texas

  • San Antonio Methodist TX Transplant Physicians Group

    San Antonio, Texas

Showing 40 of 274 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.